Free tool
FAERS Monitor: Nicotrol
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020385 or its brand name (Nicotrol, Nicotine). Reports on generic versions are filed under their own applications.
Reports
17,295
Serious
11,425
66% of reports
Hospitalization
4,810
Death reported
1,618
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective2,091
- nausea1,137
- headache789
- overdose780
- foetal exposure during pregnancy755
- nicotine dependence741
- product adhesion issue734
- dyspnoea683
- treatment noncompliance672
- malaise671
- pain632
- dizziness629
- toxicity to various agents607
- anxiety598
- off label use579
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 240 |
| 2005 | 233 |
| 2006 | 331 |
| 2007 | 445 |
| 2008 | 329 |
| 2009 | 455 |
| 2010 | 758 |
| 2011 | 701 |
| 2012 | 792 |
| 2013 | 491 |
| 2014 | 625 |
| 2015 | 713 |
| 2016 | 854 |
| 2017 | 750 |
| 2018 | 2,020 |
| 2019 | 1,265 |
| 2020 | 1,203 |
| 2021 | 934 |
| 2022 | 909 |
| 2023 | 896 |
| 2024 | 902 |
| 2025 | 847 |
| 2026 | 602 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,036,864 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| nicotine dependenceSignal | 741 | 127.9 | 118.8 | 84,360 |
| product adhesion issueSignal | 734 | 25.5 | 23.7 | 16,917 |
| treatment noncomplianceSignal | 672 | 15.1 | 14.0 | 8,755 |
| foetal exposure during pregnancySignal | 755 | 11.4 | 10.6 | 7,108 |
| overdoseSignal | 780 | 4.4 | 4.1 | 2,067 |
| toxicity to various agentsSignal | 607 | 4.4 | 4.1 | 1,592 |
| anxietySignal | 598 | 2.6 | 2.4 | 573 |
| drug ineffective | 2,091 | 1.9 | 1.9 | 999 |
| malaise | 671 | 1.9 | 1.7 | 272 |
| nausea | 1,137 | 1.7 | 1.7 | 377 |
| dizziness | 629 | 1.5 | 1.4 | 119 |
| headache | 789 | 1.5 | 1.4 | 149 |
| dyspnoea | 683 | 1.5 | 1.4 | 104 |
| pain | 632 | 1.3 | 1.2 | 33 |
| off label use | 579 | 0.8 | 0.7 | 29 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.